AABB's Statements to the Blood Product Advisory Committee

Joint Statement Before BPAC on Cold Stored Platelets for Transfusion (PDF)
Joint Statement Before BPAC on Strategies to Control the Risk of Bacterial Contamination in Platelets for Transfusion (PDF)
Joint Statement Before BPAC on August 2016 Zika Guidance Document (PDF)
Statement Before BPAC on “Blood Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products (PDF)
Joint Statement Before BPAC on FDA “Recommendation for Donor Screening, Deferral and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus,” August 2016 Guidance (PDF)
Statement Before BPAC on the Management of Iron Deficiency Associated with Blood Donation (PDF)
Statement Before BPAC on Strategies for Implementation of Testing for Babesia microti in Blood Donors (PDF)

For more information, refer to the comprehensive list of statements and comments to FDA.

Related News

FDA Seeks Comments on Biologics Reporting Requirements

October 09, 2026
FDA Investigating Hypersensitivity Reports Tied to IGIV Lot

October 07, 2026
FDA Seeks Nominations for Federal Advisory Committee Members, Including BPAC and CTGTAC

October 06, 2026